In PLoS Medicine, volume 3, issue 8: DOI: 10.1371/journal.pmed.0030330
Reference 13 was mistakenly not cited in the main article. It should have been added as a reference to the sentence: “Claims associated with costs of drug development merit careful scrutiny since they are often used as a rhetorical tool to argue for faster approval times or to justify the high price of pharmaceuticals .”
Citation: Lemmens T, Miller PB (2006) Correction: Regulating the Market in Human Research Participants. PLoS Med 3(10): e447. doi:10.1371/journal.pmed.0030447
Published: October 31, 2006
Copyright: © 2006 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.